About Intersect ENT

logo iconIntersect ENT (NASDAQ: XENT) is a medical technology company dedicated to advancing the treatment of ear, nose and throat (ENT) conditions through evidence-based innovation, providing physicians with solutions to overcome clinical challenges and improve the quality of life for patients.

Intersect ENT’s initial focus is on improving the treatment of chronic sinusitis, an inflammatory condition that affects one out of eight adults in the U.S. and has a greater impact on quality of life than congestive heart failure or chronic back pain.1,2 Chronic sinusitis often requires a complex combination of medical and surgical therapy and is hence one of the most costly conditions to U.S. employers. While traditional surgical solutions relieved symptoms in many patients, disease recurrence was frequent with the majority of patients experiencing recurrent symptoms within the first year.3

We at Intersect ENT believed there had to be a better way to improve both the patient experience and surgical outcomes. The company has developed its localized sinus drug delivery technology to do just that. Innovation backed by clinical evidence is a driving force of our company.

Intersect ENT is a publicly traded company.

1National Health Interview Survey 2006. CDC National Center for Health Statistics. Series 10 Number 235.
2Gliklich et al. Otolaryngol Head Neck Surg. 1995;113:104-9.
3Shaitkin et al. Laryngoscope. 103 Oct 2003.